eRapa (encapsulated rapamycin)

News alerts, weekly reports and conference planners

Company:

Emtora Biosci

Drug class:

mTOR inhibitor

Related drugs:

‹

›

4ms

Trial of eRapa to Prevent Progression in Familial Adenomatous Polyposis Patients Under Active Surveillance (clinicaltrials.gov)

P2, N=30, Recruiting, Rapamycin Holdings, Inc. dba Emtora Biosciences | Active, not recruiting --> Recruiting | Phase classification: P2a --> P2 | Trial completion date: Feb 2023 --> Mar 2025 | Trial primary completion date: Feb 2023 --> Mar 2025

4 months ago

Enrollment open • Phase classification • Trial completion date • Trial primary completion date

APC (APC Regulator Of WNT Signaling Pathway)

sirolimus • eRapa (encapsulated rapamycin)

6ms

Nanoliposomes Encapsulated Rapamycin/Resveratrol to Induce Apoptosis and Ferroptosis for Enhanced Colorectal Cancer Therapy. (PubMed, J Pharm Sci)

Coloading Rapa and Res into liposomes to promote apoptosis and ferroptosis in tumor cells represents a promising strategy for the treatment of colorectal cancer.

6 months ago

Journal

GPX4 (Glutathione Peroxidase 4) • SLC7A11 (Solute Carrier Family 7 Member 11)

sirolimus • eRapa (encapsulated rapamycin)

over4years

[VIRTUAL] mTORC1 suppression in Paneth cells prevents tumors in a mouse model of intestinal cancer (AACR-II 2020)

Previous research from our lab shows that an enteric release formulation of rapamycin, eRapa, enhances the lifespan of mice mutated for adenomatous polyposis coli (Apc) tumor suppressor (ApcMin/+ mice), which normally develop intestinal cancer. Although the polyps are believed to originate from stem cells, our results suggest involvement of Paneth cells in tumor prevention perhaps by signaling changes in the niche. These are novel effects of rapamycin and help define its mechanisms of cancer prevention.

over 4 years ago

Preclinical

APC (APC Regulator Of WNT Signaling Pathway)

APC mutation

sirolimus • eRapa (encapsulated rapamycin)